Prognosis of primary or metachronous prostate cancer in multiple primary genitourinary cancers; a single center experience with long-term results

Figures & data

Table 1. All patients’ age, PSA levels, pathological diagnosis, treatment methods and follow-up period are descripted.

Parameter	Age	PSA at primary tumour diagnosis	Primary tumour	Treatment of primary tumour	Time from primary to metachronous tumour (Day)	PSA at metachronous tumour diagnosis	Metachronous tumour	Size of tumour or core number of PCa cases	Treatment of metachronous tumour	Complications	Follow-up (Day)
GROUP 1
Patient 1	60	11	ISUP 1	Goserelin + Flutamid	3516	0.96	TCC-TaLG + UUT TCC	50 mm	TUR-B + RNU		7330
Patient 2	57	7.40	ISUP 1	Goserelin + Flutamid	3014	0.69	RCC-F2	55 mm	RN	CKD	3805
Patient 3	67	4.90	ISUP 1	RP	1431	0.01	TCC-T1	30 mm	TUR-B + 8 weeks MİT-C		2953
Patient 4	68	8.7	ISUP 1	AS	931	3.81	TCC-T1LG	10 mm	TUR-B		4603
Patient 5	79	8.6	ISUP 1	Goserelin	1461	0.06	TCC-TALG	20 mm	TUR-B	CKD	5192
Patient 6	68	3.51	ISUP 1	AS	3301	4.71	TCC-TALG	10 mm	TUR-B		4737
Patient 7	55	5.73	ISUP 1	AS	1149	6.00	RCC-F1 (BİLL)	34 mm	BILATERALLY PN		1365
Patient 8	61	4.4	ISUP 2	RP	3956	2.80	TCC-TALG	10 mm	TUR-B	PCa Rec.	5752
Patient 9	76	8.4	ISUP 2	Leuprorelin asetat	236	0.01	TCC-TALG	12 mm	TUR-B	PCa Rec	2936
Patient 10	63	30	ISUP 4	RP	183	0.08	TCC-TALG	7 mm	TUR-B	PCa Metastasis	510
Patient 11	63	12.4	ISUP 4	RP	3693	2.79	RCC-F2	30 mm	PN	PCa Rec	4334
GROUP 2
Patient 12	67	5	RCC-F2	RN	1739	8.30	ISUP 1	1 core	AS	Refused Treatment	6615
Patient 13	73	2.1	RCC-F2	RN	2258	4.27	ISUP 1	2 core	WW	CKD	4949
Patient 14	75	4.51	TCC-TaLG	TUR-B	396	7.51	ISUP 1	4 core	Goserelin		849
Patient 15	65	3.2	TCC-TaLG	TUR-B	539	7.20	ISUP 1	2 core (80%)	RT		1208
Patient 16	67	2	TCC-TaLG	TUR-B	208	2.53	ISUP 1	1 core	AS		1817
Patient 17	53	9.5	TCC-TaLG	TUR-B	422	4.45	ISUP 1	1 core	AS		997

ISUP: International Society of Urological Pathology; RP: radical prostatectomy; RCC: renal cell carcinoma; TCC: transitional cell carcinoma; TaLG: Ta Low Grade; T1LG: T1 Low Grade; AS: active surveillance; RN: radical nephrectomy; PSA: prostate-specific antigen; RNU: radical nephroureterectomy; TUR-B: transurethral resection of bladder; WW: watchful waiting; CKD: chronic kidney disease; MİT-C: Mitomycin-C; PN: partial nephrectomy; PCa: prostate cancer; Rec: Reccurrens; UUT: upper urinary tract.

Table 2. Statistically analyses for both groups in terms of age, smoking status, PSA levels, presence of recurrence or metatasis and follow-up periods are summarized.

Parameter	Group 1 (G1) n = 11 Median (IQR)	Group 2 (G2) n = 6 Median (IQR)	All patients n = 17 Median (IQR)	p-Value (G1–G2)
Age at diagnosis (Year)	63 (60–68)	67 (65–73)	67 (60.5–70.5)	0.733
Age (Year)	80 (75–83)	78.5 (69–86)	80 (71–84.5)	0.960
Smoking status (pack year)	0 (0–45)	20 (0–50)	0 (47.5)	0.660
PSA (ng/mL)	7.4 (4.4–8.7)	5.82 (3.4–7.9)	7.2 (4.33–8.5)	0.108
Follow-up (Years)	11.87 (8.04–14.22)	4.14 (2.52–15.84)	10.42 (3.52–13.89)	0.315
Recurrence or metastasis (−/+)	3 Biochemical recurrence 1 metastasis	None	4 Biochemical recurrence or metastasis	0.091